涂阳肺结核病人发现程序的探讨

目的　探索高发现、操作简便、成本低的病人发现程序。方法 山东省2000年结核病流行病学抽样调查资料。结果 在1715例同时胸透和痰涂片检查的可疑肺结核症状者中,发现涂阳肺结核病人51例,其中胸透诊断正常者15例。结论 对可疑肺结核症状者必须全部查痰。     

BACTEC MGIT 960培养结合INNO-LIPA~(TM) RIF.TBDNA探针新技术快速诊断结核病

目的通过MGIT960培养系统结合国外最新的INNO -LIPATM RIF.TB(LIPA)DNA探针技术的应用 ,探讨其快速诊断结核病的可行性。方法应用BACTECMGIT960系统进行临床疑似结核病例标本的培养 ,筛选了70例结核分枝杆菌 ,35例非结核分枝杆菌 ,用LIPA探针技术诊断是否为结核分枝杆菌。结果用LIPADNA方法在70例结核分枝杆菌中获得阳性69例 ,占98.6 % ;35例非结核分枝杆菌均为阴性。与单纯消化纯化后涂片的82.9 % (58/70)的阳性率相比增加了15.7个百分点 ,两者在统计学上差异有显著性(P<0.05)。BactecMGIT960培养结合LIPADNA探针与传统诊断方法4～8周相比 ,整个过程只需6～37天 ,平均15天 (2周 )。结论LIPADNA探针是一种具有高度敏感性和特异性、能够简便、快速、准确地诊断结核病的新技术。同时还能鉴定rpoβ 基因位点的突变 ,诊断耐利福平 (RMP)性结核 ,有望适用于结核分枝杆菌耐RMP性结核的快速检测 ,进一步为结核病快速准确的治疗提供理论依据。     

The use of freeze-dried allograft bone for anterior cervical fusions

A consecutive series of 87 patients undergoing Smith-Robinson anterior cervical fusion were analyzed. Either freeze-dried tricortical iliac crest bone or tricortical autograft bone was used. Surgical technique was otherwise identical. Radiography showed delayed union at 3 months in 13% of patients with autograft and in 37% of patients with freeze-dried allograft. At 1 year, radiography showed nonunion in 8% of patients with autograft and in 22% of patients with allograft. One-level procedures had a delayed union rate of 7% for autograft and 21% for allograft. Nonunion in one-level procedures was 5% for both autograft and allograft. For two-level procedures, the nonunion rate was 17% for autograft and 63% for allograft. Graft collapse was more commonly seen with freeze-dried allograft (30%) than with autograft (5%). Relief of neck and arm pain, however, was similar in both groups.     

安徽省实施结核病控制日本援助项目两年效果与评价

目的　了解两年来全省日本援助结核病控制项目县的实施情况。方法　按项目实施指南要求 ,检查2 0 0 2 -2 0 0 3年启动项目县有关结核病归口管理、结核病人的发现、治疗及管理情况 ,并现场作督导记录。结果　项目实施两年来 ,发现并入项涂阳结核病人 12 5 14例 ;2 0 0 2年入项的涂阳病人转归初治治愈率 86.3 % ,复治治愈率 70 .0 % ;2 0 0 3年入项的涂阳病人 2个月治疗后痰菌转阴率 ,初复治分别为 84.8%、70 % ;综合医院结核病转诊率平均 47.3 %。结论　项目工作进展较为顺利 ,但各项目县发展不平衡 ;切实落实结核病归口管理 ,加强病人发现工作 ,同时要特别加大对复治涂阳病人的督导管理力度 ,是做好项目“高治愈、高发现”的关键。     

A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration

The objective of this study was to compare the bioavailability of s.c. and i.m. administration of human chorionic gonadotrophin (HCG; Pregnyl). In a randomized, single-centre, three-way cross-over study, 18 healthy pituitary-suppressed volunteers were assigned to single HCG injections of 5000 and 10,000 IU i.m. and 10,000 IU s.c. Rate (Cmax, t(max)) and extent [area under curve from zero to infinity (AUC(0- infinity))] of absorption of HCG were determined. Serum immunoactive HCG increased from 0.4-0.5 IU/l at baseline to mean peak concentrations, which were reached 20 h after injection of 156 IU/l with 5000 IU i.m., of 307 IU/l with 10,000 IU i.m. and of 339 IU/l with 10,000 IU s.c. Eight days after administration, < 10% of the maximum HCG activity was found for each regimen. The elimination half-life (t(1/2)) was on average 32-33 h, irrespective of the treatment regimen. Intramuscular and s.c. injections of 10,000 IU HCG were bioequivalent with respect to AUC(0-infinity). The Cmax and t(max) were also similar between the two administration routes but bioequivalence could not be proven due to intersubject variability. Intramuscular doses of 5000 IU and 10,000 IU HCG were dose-proportional. Since s.c. HCG is bioequivalent to i.m. HCG with respect to extent of absorption (its major pharmacokinetic variable) and is well tolerated, the s.c. administration route may be effectively and safely used in assisted reproduction. Moreover, since s.c. injection can be performed by the patients themselves, acceptability may be enhanced.      

Syringomyelia: a neurological and surgical spectrum

Because of the variation in the natural history, anatomy, surgical treatment, and follow-up periods reported to date, very few firm conclusions can be drawn regarding syringomyelia. With the advent of magnetic resonance scanning, cases of syringomyelia are being detected earlier and a better understanding of the disease has been facilitated. The authors report their personal experiences with 21 patients followed for 5-20 years. No single surgical procedure appears to predictably remedy any syrinx for more than a brief period of several years. Complete collapse of the syrinx does not eradicate all symptoms. Direct treatment of the syrinx makes intuitive sense for those syrinxes that do not communicate with the fourth ventricle. On the other hand, for syrinxes that are likely to communicate with the fourth ventricle, shunting of the ventricular system, particularly where ventriculomegaly exists (i.e., any degree of radiographic evidence of ventricular enlargement), should be considered initially. Procedures such as posterior fossa decompression may be necessary as dictated by the neurological condition of the patient. In the authors' experience, shunting procedures provided better improvement, with longer duration of improvement than with posterior fossa decompression. The timing and surgical details of posterior fossa decompression remain to be elucidated.     

Management of testicular seminoma following organ transplantation

An increased incidence of malignancies has occurred in recipients of organ transplantation who are immunosuppressed. Although testicular cancers have been uncommon, seminomas are extremely rare. Two patients with long-standing diabetes mellitus and renal transplants developed clinical stage I seminoma of the testis. These patients posed a therapeutic problem with respect to the use of radiation therapy. In one, none was given because of a combination of kidney rejection and antibiotic-induced renal damage. The second patient received radiation therapy with shielding of the transplanted kidney. The surgical distortion of lymph node architecture increases the problems in the use of radiation therapy. Individual factors need to be considered in the use of postorchiectomy radiation therapy for seminoma in transplant patients. © 1992 Wiley-Liss, Inc.